![]() |
Indiana Administrative Code (Last Updated: December 20, 2016) |
![]() |
Title 410. INDIANA STATE DEPARTMENT OF HEALTH |
![]() |
Article 410IAC3.2. CHILDREN WITH SPECIAL HEALTH CARE NEEDS |
![]() |
Rule 410IAC3.2-6. Eligibility |
Section 410IAC3.2-6-2. Medical eligibility
-
(a) To be medically eligible for the CSHCN program, a child shall meet the following requirements:
(1) Be under twenty-one (21) years of age.
(2) Have a physical condition that has lasted or is expected to last at least two (2) years if not treated and the physical condition necessitates more health care services than are usually required for a child of that age.
(3) The physical condition also produces or will produce:
(A) disability;
(B) disfigurement;
(C) limitation of function;
(D) the need for a special diet; or
(E) dependence on an assistive device;
or nonintervention will, within one (1) year, lead to a chronic disabling physical condition.
(4) Have at least one (1) of the eligible medical conditions defined in subsection (b).
(b) For a child not enrolled in the program as of December 31, 1992, the medical conditions eligible for the CSHCN program are the following:
(1) Apnea defined by one (1) or more of the following criteria:
(A) Infants at high risk for recurring apnea defined by one (1) or more of the following criteria:
(i) Infants with one (1) or more severe apparent life threatening events (ALTE) requiring resuscitation or vigorous stimulation.
(ii) Preterm infants with symptomatic apnea.
(iii) Infants who have had two (2) or more siblings that have been Sudden Infant Death Syndrome (SIDS) victims.
(iv) Infants at high risk of apnea from medical conditions such as:
(AA) central hypoventilation syndrome;
(BB) myotonic dystrophy; or
(CC) Arnold Chiari malformation.
(B) Infants at possible increased risk for recurring apnea defined by one (1) or more of the following criteria:
(i) Infants with tracheostomies.
(ii) Infants with craniofacial anomalies such as Pierre Robin.
(iii) Infants with bronchopulmonary dysplasia.
(iv) Infants with myelodysplasia.
(C) Infants shall be reassessed for the need for continued monitoring at least every six (6) months.
(2) Arthritis resulting in disability.
(3) Asthma defined by one (1) or more of the following criteria:
(A) Requiring daily therapy with two (2) or more prescription medications, including, but not limited to, the following:
(i) Inhaled bronchodilators.
(ii) Inhaled cromolyn.
(iii) Inhaled corticosteroid.
(iv) Theophylline.
(v) Oral steroids (daily or every other day).
(vi) Inhaled ipratropium bromide or atropine.
(B) Despite taking appropriate daily medication, more than two (2) hospitalizations for asthma, each lasting at least four (4) days, have occurred within the last twelve (12) months.
(C) Hospitalization for asthma has been required for more than fifteen (15) days in a single twelve (12) month period.
(4) Cerebral palsy or other static encephalopathy resulting in loss of motor function or dysarthria.
(5) Chronic anemia requiring two (2) or more blood transfusions or resulting in two (2) or more crises requiring hospitalization.
(6) Cleft lip or palate, or both.
(7) Congenital or acquired developmental deformities.
(8) Congenital heart disease or arrhythmias requiring electrophysiologic studies, catheterization, or surgery on the heart or major vessels.
(9) Chromosomal disorders resulting in loss of motor function or expressive language function.
(10) Chronic pulmonary disease defined by one (1) or more of the following criteria:
(A) Oxygen dependent as defined by requiring supplemental oxygen to maintain a resting PO2 greater than seventy (70) millimeters of mercury or an oxygen saturation greater than ninety-two percent (92%).
(B) Requiring oxygen (same criteria as in clause (A)) during feeding or during sleep.
(C) Requiring continuous positive alveolar pressure (CPAP).
(D) Requiring three (3) or more medicines or treatments, including, but not limited to, the following:
(i) Inhaled bronchodilator.
(ii) Inhaled antiinflammatory drugs, such as Intal or corticosteroids.
(iii) Daily theophylline.
(iv) Daily diuretics.
(v) Antihypertensive medication.
(vi) Digoxin.
(vii) High calorie feedings or nutritional supplements.
(viii) Gastrostomy or naso-oro gastric/duodenal/jejunal feedings.
(ix) Tracheostomy.
(x) Home cardiorespiratory monitor.
(xi) Mechanical ventilation, full-time or part-time.
(xii) Other technologic support, such as feeding pump or suction equipment.
(xiii) Home oxygen therapy for longer than two (2) months.
(11) Cystic fibrosis.
(12) Endocrine deficiencies requiring the following replacement therapy longer than five (5) years, including the following:
(A) Hypothyroidism.
(B) Adrenocortical insufficiency.
(C) Insulin dependent diabetes mellitus.
(D) Panhypopituitarism.
Growth hormone therapy for isolated short stature without other medical indications is not an eligible medical condition.
(13) Bilateral hearing loss greater than forty (40) decibels.
(14) Hemophilia requiring factor replacement at least two (2) times a year.
(15) Hydrocephalus requiring or likely to require a shunt during childhood.
(16) Inflammatory bowel disease requiring multiple hospitalizations within the past two (2) years, resection of the bowel, or hyperalimentation for longer than one (1) month.
(17) Inborn errors of metabolism that have a potential for a significantly improved outcome if treated with a special diet or prescription medication.
(18) Neuromuscular dysfunction.
(19) Myelodysplasia or other spinal cord dysfunction.
(20) Oncologic disorders.
(21) Progressive or chronic renal disease with hypertension or renal insufficiency.
(22) Epilepsy requiring daily prescription medication.
(23) Autism.
(Indiana State Department of Health; 410 IAC 3.2-6-2; filed Apr 12, 1993, 5:00 p.m.: 16 IR 2177; readopted filed Jul 11, 2001, 2:23 p.m.: 24 IR 4234; readopted filed May 22, 2007, 1:44 p.m.: 20070613-IR-410070141RFA; filed Sep 29, 2009, 3:23 p.m.: 20091028-IR-410090001FRA, eff Jan 1, 2010; readopted filed Sep 11, 2013, 3:19 p.m.: 20131009-IR-410130346RFA)